Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy

Journal of NeuroVirology

Volumn 18, Issue 6, 2012, Pages 479-487

  Bunupuradah, Torsak ^a   Chetchotisakd, Ploenchan ^b   Jirajariyavej, Supunnee ^c   Valcour, Victor ^d   Bowonwattanuwong, Chureeratana ^e   Munsakul, Warangkana ^f   Klinbuayaem, Virat ^g   Prasithsirikul, Wisit ^h   Sophonphan, Jiratchaya ^a   Mahanontharit, Apicha ^a   Hirschel, Bernard ⁱ   Bhakeecheep, Sorakij ^j   Ruxrungtham, Kiat ^a,k   Ananworanich, Jintanat ^a,k,l  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c Taksin Hospital   (Thailand)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CHONBURI HOSPITAL   (Thailand)

^f NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^g Sanpatong Hospital   (Thailand)

^h Bamrasnaradura Infectious Disease Institute   (Thailand)

ⁱ UNIVERSITY OF GENEVA   (Switzerland)

^j National Health Security Office   (Thailand)

^k CHULALONGKORN UNIVERSITY   (Thailand)

^l THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

more..

Author keywords

Central nervous system penetration effectiveness score; Depression; Lopinavir ritonavir monotherapy; Neurocognitive impairment

Indexed keywords

CD4 ANTIGEN; LAMIVUDINE; LAMIVUDINE PLUS LOPINAVIR PLUS RITONAVIR PLUS TENOFOVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PREDICTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE; VIREMIA;

ADENINE; ADULT; CD4 LYMPHOCYTE COUNT; COGNITION DISORDERS; DEPRESSION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; LOPINAVIR; MALE; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; VIRAL LOAD;

THAIS;

EID: 84875740369     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-012-0127-9     Document Type: Article

References (28)

1. Agsalda M, Kusao I, Troelstrup D, Velasco V-N, Shikuma C, Valcour V et al (2012) Monocytes with an inflammatory profile and high HIV DNA copy numbers characterize patients with neurocognitive deficits. Poster number 460. The 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012), Seattle, WA, USA
2. Arribas JR, Delgado R, Arranz A, Munoz R, Portilla J, Pasquau J et al (2009) Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 51(2):147-152
3. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA (2009) HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 23(3):279-291
4. Bunupuradah T, Chetchotisakd P, Ananworanich J, Munsakul W, Jirajariyavej S, Kantipong P et al (2012) A randomized comparison of second-line lopinavir/ritonavir monotherapy vs. tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI-regimens: the HIV STAR study. Antivir Ther. doi: 10.3851/IMP2222
5. Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, Bracciale L et al (2011) Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 76(16):1403-1409
6. Clotet B, Gomez JL (2011) Clinical study to evaluate the efficacy and safety of lopinavir/ritonavir monotherapy versus darunavir/ritonavir monotherapies as simplification switching strategies of PI/NNRTI-triple therapy based-regimens. NCT00994344. http://clinicaltrials.gov/ct2/show/NCT00994344? term=darunavir+monotherapy&rank=1. Accessed 5 Dec 2011.
7. Gonzalez-Scarano F, Martin-Garcia J (2005) The neuropathogenesis of AIDS. Nat Rev 5(1):69-81
8. Gutmann C, Cusini A, Gunthard HF, Fux C, Hirschel B, Decosterd LA et al (2010) Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 24(15):2347-2354
9. Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar E et al (2011) Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 25(5):625-633
10. Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S et al (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17(1):3-16
11. Letendre SL, Ellis RJ, Ances BM, McCutchan JA (2010) Neurologic complications of HIV disease and their treatment. Top HIV Med 18(2):45-55
12. Liu Y, Tang XP, McArthur JC, Scott J, Gartner S (2000) Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J Neurovirol 6(Suppl 1):S70-S81
13. Lotrakul M, Sukanich P (1999) Development of the Thai Depression Inventory. J Med Assoc Thai 82(12):1200-1207
14. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K et al (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23(11):1359-1366
15. Munoz-Moreno JA, Fumaz CR, Ferrer MJ, Prats A, Negredo E, Garolera M et al (2008) Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses 24(10):1301-1307
16. Paton N et al. (2011) A randomized controlled trial of a strategy of switching to boosted protease inhibitor monotherapy versus continuing combination antiretroviral therapy for the long-term management of HIV-1 infected patients who have achieved sustained virological suppression on highly-active antiretroviral therapy. ISRCTN04857074. http://controlled-trials. com/ISRCTN04857074/pivot. Accessed 5 Dec 2011.
17. Perez-Valero I, Bayon C, Cambron I, Gonzalez A, Arribas JR (2011) Protease inhibitor monotherapy and the CNS: peace of mind? J Antimicrob Chemother 66(9):1954-1962
18. Pulido F, Matarranz M, Rodriguez-Rivera V, Fiorante S, Hernando A (2010) Boosted protease inhibitor monotherapy. What have we learnt after seven years of research? AIDS Rev 12(3):127-134
19. Pumpradit W, Ananworanich J, Lolak S, Shikuma C, Paul R, Siangphoe U et al (2010) Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study. J Neurovirol 16(1):76-82
20. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J et al (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21(14):1915-1921
21. Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB et al (2011) Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 25(3):357-365
22. Valcour VG, Sithinamsuwan P, Nidhinandana S, Thitivichianlert S, Ratto-Kim S, Apateerapong W et al (2007) Neuropsychological abnormalities in patients with dementia in CRF 01-AE HIV-1 infection. Neurology 68(7):525-527
23. Valcour VG, Shiramizu BT, Sithinamsuwan P, Nidhinandana S, Ratto-Kim S, Ananworanich J et al (2009) HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study. Neurology 72(11):992-998
24. Valcour V, Sithinamsuwan P, Letendre S, Ances B (2010) Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep 8(1):54-61
25. Valcour V, Paul R, Chiao S, Wendelken LA, Miller B (2011) Screening for cognitive impairment in human immunodeficiency virus. Clin Infect Dis 53(8):836-842
26. Vernazza P, Daneel S, Schiffer V, Decosterd L, Fierz W, Klimkait T et al (2007) The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS 21(10):1309-1315
27. Vivithanaporn P, Nelles K, Deblock L, Newman SC, Gill MJ, Power C (2012) Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS. J Neurol Sci 312(1-2):45-51
28. Zogg JB, Woods SP, Weber E, Iudicello JE, Dawson MS, Grant I (2010) HIV-associated prospective memory impairment in the laboratory predicts failures on a semi-naturalistic measure of health care compliance. Clin Neuropsychol 24(6):945-962